Cargando…

CXCR3(+) T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria

A malaria vaccine strategy targeting multiple lifecycle stages may be required to achieve a high level of efficacy. In two Phase IIa clinical trials, we tested immunogenicity and efficacy of RTS,S/AS01B administered alone, in a staggered regimen with viral-vectored vaccines or co-administered with v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bowyer, Georgina, Grobbelaar, Amy, Rampling, Tommy, Venkatraman, Navin, Morelle, Danielle, Ballou, Ripley W., Hill, Adrian V. S., Ewer, Katie J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068239/ https://www.ncbi.nlm.nih.gov/pubmed/30090099 http://dx.doi.org/10.3389/fimmu.2018.01660

Ejemplares similares

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
por: Rampling, Tommy, et al.
Publicado: (2018)

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01(B) With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP
por: Rampling, Tommy, et al.
Publicado: (2016)

A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01(E) and RTS,S/AS01(B) Delayed Fractional Dose Regimens in Malaria-Naive Adults
por: Moon, James E, et al.
Publicado: (2020)

Mosquirix™ RTS, S/AS01 Vaccine Development, Immunogenicity, and Efficacy
por: Nadeem, Aroosa Younis, et al.
Publicado: (2022)

A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon
por: Lell, Bertrand, et al.
Publicado: (2009)

Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area
por: Polhemus, Mark E., et al.
Publicado: (2009)

Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid
por: Lambe, Teresa, et al.
Publicado: (2016)

Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on Genotypes of P. falciparum in Adults Participating in a Malaria Vaccine Clinical Trial
por: Waitumbi, John N., et al.
Publicado: (2009)

Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data
por: Moorthy, Vasee S, et al.
Publicado: (2009)

A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses
por: Pallikkuth, Suresh, et al.
Publicado: (2020)

The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01
por: Fortpied, Juliette, et al.
Publicado: (2020)

Activation-induced Markers Detect Vaccine-Specific CD4(+) T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials
por: Bowyer, Georgina, et al.
Publicado: (2018)

Impact of high human genetic diversity in Africa on immunogenicity and efficacy of RTS,S/AS01 vaccine
por: Tukwasibwe, Stephen, et al.
Publicado: (2023)

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
por: Venkatraman, Navin, et al.
Publicado: (2019)

Correlations between three ELISA protocols measurements of RTS,S/AS01-induced anti-CSP IgG antibodies
por: Mugo, Robert M., et al.
Publicado: (2023)

Randomized Controlled Trial of RTS,S/AS02(D) and RTS,S/AS01(E) Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children
por: Owusu-Agyei, Seth, et al.
Publicado: (2009)

Correction: Randomized Controlled Trial of RTS,S/AS02(D) and RTS,S/AS01(E) Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children
por: Owusu-Agyei, Seth, et al.
Publicado: (2010)

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa
por: Leach, Amanda, et al.
Publicado: (2011)

CXCR5, the Defining Marker for Follicular B Helper T (T(FH)) Cells
por: Moser, Bernhard
Publicado: (2015)

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults
por: Ockenhouse, Christian F., et al.
Publicado: (2015)

Safety of the Malaria Vaccine Candidate, RTS,S/AS01(E) in 5 to 17 Month Old Kenyan and Tanzanian Children
por: Lusingu, John, et al.
Publicado: (2010)

The Future of the RTS,S/AS01 Malaria Vaccine: An Alternative Development Plan
por: Gosling, Roly, et al.
Publicado: (2016)

Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01(E) in 5 to 17 Month Old Kenyan and Tanzanian Children
por: Lusingu, John, et al.
Publicado: (2010)

Correction: Safety of the Malaria Vaccine Candidate, RTS,S/AS01(E) in 5 to 17 Month Old Kenyan and Tanzanian Children
por: Lusingu, John, et al.
Publicado: (2010)

Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02(D) Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial
por: Aide, Pedro, et al.
Publicado: (2010)

Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report
por: Merle, Corinne S.
Publicado: (2023)

Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi
por: Bell, Griffin J., et al.
Publicado: (2020)

Towards Eradication of Malaria: Is the WHO’s RTS,S/AS01 Vaccination Effective Enough?
por: Arora, Navneet, et al.
Publicado: (2021)

Should India be considering deployment of the first malaria vaccine RTS, S/AS01?
por: Rahi, Manju, et al.
Publicado: (2022)

RTS,S/AS01 Malaria Vaccine - The Next Step for a Developing Country
por: ZEHRA, ASMAT, et al.
Publicado: (2022)

RTS,S/AS01 malaria vaccine (Mosquirix(®)): a profile of its use
por: Syed, Yahiya Y.
Publicado: (2022)

Acceptance, availability, and feasibility of RTS, S/AS01 malaria vaccine: A review
por: Mumtaz, Hassan, et al.
Publicado: (2023)

A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?
por: Lambe, Teresa, et al.
Publicado: (2017)

Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region
por: Abdulla, Salim, et al.
Publicado: (2013)

T Cell Responses to the RTS,S/AS01(E) and RTS,S/AS02(D) Malaria Candidate Vaccines Administered According to Different Schedules to Ghanaian Children
por: Ansong, Daniel, et al.
Publicado: (2011)

Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial
por: van den Berg, Robert A., et al.
Publicado: (2017)

CXCR5(+)PD-1(+) follicular helper CD8 T cells control B cell tolerance
por: Chen, Yuhong, et al.
Publicado: (2019)

Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa
por: Otieno, Lucas, et al.
Publicado: (2020)

Simulated Impact of RTS,S/AS01 Vaccination Programs in the Context of Changing Malaria Transmission
por: Brooks, Alan, et al.
Publicado: (2012)

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial
por: White, Michael T, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p71rhbspakm259sg8pld9grml6